Get started
Author

Alia C. Lynch

Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases
2025 · Fabian J. Bolte, Sean C. Dougherty, et al. · Clinical Lung Cancer · 42
PDF
Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
2021 · Sean C. Dougherty, Alia C. Lynch, et al. · Clinical Case Reports · 10
PDF
Rapid Response to Pembrolizumab in a Critically Ill Mechanically Ventilated Patient with New Diagnosis of NSCLC
2019 · Erin M. McLoughlin, James M. Larner, et al. · Journal of Thoracic Oncology · 8
First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report
2024 · Alissa J. Cooper, Natasha Rekhtman, et al. · JTO Clinical and Research Reports · 5
PDF
Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase
2018 · Thomas E Schultz, Alia C Lynch · Journal of Oncology Pharmacy Practice · 4
Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network
2025 · Shawn P Griffin, Jessie Signorelli, et al. · Journal of Oncology Pharmacy Practice · 2
Safety and Efficacy of Tarlatamab in Small Cell Lung Cancer, Including Patients with Untreated Brain Metastases
2025 · Fabian Bolte, Sean Dougherty, et al. · SSRN Electronic Journal · 2
Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis
2026 · Sean C. Dougherty, Rishika Singh, et al. · Frontiers in Oncology · 1
PDF
Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report
2022 · Lindsey B. Shantzer, Sean C. Dougherty, et al. · Clinical Lung Cancer · 1
Real world analysis of VTE incidence in lung cancer: A comprehensive assessment of the Khorana score and other clinical factors in predicting VTE incidence.
2025 · Rishika Singh, Caleb McKinney, et al. · Journal of Clinical Oncology
PDF
PP01.135 Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III NSCLC: A Multi-Center Study
2024 · Philip Young, John Sharp, et al. · Journal of Thoracic Oncology
PDF
803 Immune-related adverse events correlate with improved outcomes in patients with advanced non-small cell lung cancer treated with combinations of immune-checkpoint inhibitors and chemotherapy
2021 · Lindsey Shantzer, Sean Dougherty, et al. · Regular and Young Investigator Award Abstracts
PDF
Real-World Evaluation of Hematologic Toxicity Associated with nab-Paclitaxel Plus Gemcitabine for Advanced Pancreatic Cancer
2015 · Alia Lynch, Jeremy Sen, et al. · American journal of cancer research and clinical oncology
Works count: 13
Citation count: 75
H-index: 4
I10-index: 2
Year
Topic
Type